CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
Immunethep has developed a novel vaccine that protects against infections from five major bacteria by targeting a specific immunosuppressive protein they produce. This innovative approach enhances the host's immune response, enabling effective defense against these pathogens, including multi-resistant strains.
Immunethep has developed, patented (WO/2015/189422), and successfully undergone preclinical trials for a new breakthrough vaccine (PNV-Paragon Novel Vaccine).
It protects against bacterial infections caused by 5 different bacteria:
S. aureus, S. pneumoniae, K. pneumoniae, E. coli and GBS.
Our innovation relies on the discovery of a virulence and immunosuppressive mechanism common to these pathogens.
The bacteria excrete a highly immunosuppressive protein designated as glyceraldehyde-3-phosphate…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
